1. Scrip
  2. >>Business
  3. >>Earnings

Vertex Outlines Next Development Steps For Suzetrigine In Pain

 
• By Jessica Merrill

The company has accelerated a Phase II trial testing the NaV1.8 inhibitor in lumbosacral radiculopathy, and a Phase III trial in diabetic peripheral neuropathy will start this quarter.

Vertex updated investors on its diversification strategy • Source: Shutterstock

Vertex Pharmaceuticals Incorporated is already awaiting US Food and Drug Administration approval for its NaV1.8 inhibitor suzetrigine for the treatment of moderate-to-severe acute pain, but the company is advancing the drug into other late-stage clinical trials, with an eye toward expansion in peripheral neuropathic pain.

Key Takeaways
  • Vertex updated investors on Phase III development plans for the NaV1.8 inhibitor suzetrigine and povetacicept for IgA nephropathy (IgAN).

The company updated investors on the development of suzetrigine and other next-generation NaV1.8 and NaV1.7 inhibitors during its second quarter...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 
• By Sushmita Panda

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.